Webinar Focuses on Importance of Maintaining Independence for Progressive MS Patients
When a progressively debilitating disease like multiple sclerosis (MS) causes a patient to feel physically “wiped out” after a…
Kara Elam is currently working on her Doctorate in Health Policy. She holds Master Degrees in both epidemiology and microbiology. Her research interests include emerging viral diseases, the intersection of human rights and intellectual property rights, and ending violence against women.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
When a progressively debilitating disease like multiple sclerosis (MS) causes a patient to feel physically “wiped out” after a…
The Americas Committee for the Treatment and Research in Multiple Sclerosis, otherwise known as ACTRIMS, says its third annual ACTRIMS Forum will take place Feb. 1-3, 2018, at the Hilton San Diego Bayfront in San Diego, California. These forums bolster the ACTRIMS mission, which is to foster the careers of young researchers interested in MS by promoting mentor relationships with senior scientists, and giving promising investigators a chance to present their early research findings. ACTRIMS 2017 was a record-breaking year with over 800 people attending. Organizers say 1,000 people will attend this year's conference. The 2018 forum's theme is “Therapeutic Targets in MS: The Frontier and the Future of Disease Modifying Therapy.” ACTRIMS 2018 also features continuing medical education credits for attendees, as well as participation grants for applicable young investigators.
Multiple sclerosis (MS) patients who used the RebiSmart (Merck Serono) device to inject themselves with interferon beta-1a (INF β-1a)…
Researchers from Oryzon will present efficacy data on the company’s oral epigenetic drug ORY-2001, a potential treatment for multiple sclerosis (MS), at…
Biogen, a global biotechnology company with over 30 years of clinical excellence in Multiple Sclerosis (MS) research, has recently announced…
This week, Belgian-based biopharmaceutical company Ablynx announced they have entered into an exclusive research collaboration with Genzyme, a Sanofi…
This week the Consortium of Multiple Sclerosis Centers (CMSC) in collaboration with The France Foundation, a provider…
A study published by a team of investigators at the University of Tokyo’s Institute of Medical Science…
Get regular updates to your inbox.